The 100% Pharma Tariff Is Real: How to Apply for Relief Before June 12

The Commerce Department published its Section 232 pharmaceutical onshoring procedures today — and you have exactly 30 days to apply. If your company imports patented drugs or APIs, the difference between a 100% tariff and a 0% tariff comes down to what you file by June 12, 2026.

On April 2, 2026, President Trump signed Proclamation 11020 imposing 100% Section 232 tariffs on patented pharmaceuticals and their active pharmaceutical ingredients. The industry spent six weeks asking the same question: how do we actually get the reduced rates the proclamation promised?

Today, we have the answer. The Bureau of Industry and Security published a Federal Register notice on May 13 laying out the company-specific onshoring agreement process. It's not an exclusion request. It's not a product-level petition. It's a negotiated deal between your company and the U.S. government — and the application window closes June 12, 2026.

The stakes are staggering. The U.S. imports roughly $200 billion in pharmaceuticals annually. For companies that don't act, the full 100% rate kicks in on July 31 for the 17 named Annex III companies, and September 29 for everyone else. For companies that do act, the rate drops to 20% — or zero, if you also sign a Most Favored Nation pricing agreement with HHS.

What Section 232 Pharmaceutical Tariffs Actually Cover

The proclamation targets every patented pharmaceutical product listed in the FDA's Orange Book or Purple Book, plus every active pharmaceutical ingredient (API) and key starting material used to manufacture those products. The covered goods span more than 130 HTSUS subheadings across Chapter 29 (organic chemicals) and Chapter 30 (pharmaceutical products), organized under the new tariff code family 9903.04.60 through 9903.04.69.

Here's what's critical to understand: "patented" means currently subject to a valid, unexpired U.S. patent. If your drug goes generic, it exits the tariff scope. If it's still patent-protected and listed in the Orange Book or Purple Book, it's covered — regardless of where it's manufactured.

The tariff applies as a floating rate. Where a covered product already has a non-zero Column 1 MFN rate, the Section 232 tariff fills the gap up to 100%. If the existing MFN rate already exceeds 100%, only the MFN rate applies. The tariffs do not stack on top of existing duties — importers pay whichever is higher.

The Tiered Rate Structure: Four Paths, Four Prices

Unlike Section 232 steel and aluminum — where importers petition BIS for product-by-product exclusions — the pharmaceutical proclamation uses company-level agreements as the primary relief mechanism. There is no product exclusion process.

The gap between 100% and 20% — or 100% and 0% — represents potentially billions of dollars in duty exposure. For a company importing $500 million in patented APIs annually, the difference between the standard rate and the onshoring tier is $400 million per year in duties.

What the BIS Notice Requires: The Application Process

The May 13 Federal Register notice establishes a negotiated, company-specific mechanism — not a general exclusion process. Here's what Commerce is asking for:

Submission deadline: June 12, 2026 (30 days from publication)

Where to submit: [email protected]

Required information in your application:

• Detailed commitments to onshore production of patented pharmaceuticals, APIs, and upstream pharmaceutical ingredients
• Current share of U.S. and global sales manufactured domestically vs. imported
• Timeline and capital expenditure plan for U.S.-based production facilities
• Specific products and HTS classifications covered by your onshoring commitment
• Employment projections for U.S. manufacturing operations
• Supply chain mapping showing current foreign dependencies

Commerce will evaluate applications and negotiate company-specific agreements. Approved companies receive formal notification and their reduced rate applies from the relevant effective date — meaning if you're approved before September 29, you never pay the full 100%.

Who Faces the July 31 Deadline: The Annex III Companies

Seventeen named companies face an accelerated timeline. Their 100% tariff takes effect July 31, 2026 — two months before everyone else. These are the largest pharmaceutical importers, and they were given notice in the original April 2 proclamation specifically because of their scale.

While the full Annex III list names specific corporate entities, the companies facing this earlier deadline include major multinational pharmaceutical manufacturers with significant import volumes into the United States. If your company is listed in Annex III, your onshoring application is even more urgent — you have less than 80 days before the full rate hits.

For companies not in Annex III, the September 29, 2026 effective date provides a slightly longer runway. But the June 12 application deadline is the same for everyone. Missing that window doesn't mean you can't negotiate later — but it means you start paying 100% while you negotiate.

What's Exempt: Products That Don't Face the 100% Rate

Not everything in Chapter 29 and 30 is covered. The proclamation carves out several categories entirely:

• Generic pharmaceuticals and their associated APIs (formal review mandated within one year)
• Orphan drugs where all approved indications are designated under the Orphan Drug Act
• Nuclear medicines
• Plasma-derived therapies
• Fertility treatments
• Cell and gene therapies
• Antibody drug conjugates
• Medical countermeasures for CBRN threats
• Animal health pharmaceuticals

There's a catch: these exemptions require a determination by the Secretary of HHS that the products either (1) come from a jurisdiction with a current or forthcoming trade and security framework agreement, or (2) meet an urgent United States health need. The exemptions aren't automatic — they depend on HHS action.

The MFN Pricing Agreement: Zero Percent, But at What Cost

The most attractive tier — 0% until January 20, 2029 — requires both an onshoring plan and a Most Favored Nation pricing agreement with HHS. The MFN element means committing to charge U.S. government payers no more than the lowest price you offer to any comparable foreign government.

For pharmaceutical companies, this is a fundamental business model decision, not just a tariff calculation. MFN pricing has been debated in Washington for years — this proclamation makes it voluntary but attaches an enormous financial incentive. The question for each company is whether the tariff savings from 0% duty justify the revenue impact of price equalization.

Companies evaluating this path should model both scenarios: (1) the 20% rate with onshoring only, maintaining current pricing flexibility, versus (2) the 0% rate with MFN pricing, accepting lower margins on government sales in exchange for duty-free imports. For high-volume API importers, the duty savings alone could exceed the pricing concession.

What Customs Brokers Need to Do Right Now

If you're a broker handling pharmaceutical entries, you're about to become the most important phone call your clients make. Here's your action list:

1. Audit your pharmaceutical clients' import portfolios — Identify every entry containing products under HTS Chapters 29 and 30 that are patented and listed in the Orange Book or Purple Book. These are your exposed entries.

2. Flag the Annex III clients immediately — Any client on the Annex III list faces a July 31 effective date. They need to know today that their onshoring application is due June 12 and their tariff exposure starts in less than 80 days.

3. Model the duty impact — Calculate the difference between 100%, 20%, and 0% on each client's annual pharmaceutical import volume. Present this in dollars, not percentages. A client importing $50 million in APIs needs to hear "$40 million in annual duties" versus "$10 million."

4. Connect clients with trade counsel — The onshoring application isn't a one-page form. It requires detailed manufacturing commitments, capital expenditure timelines, and supply chain documentation. Clients need legal and strategic support to negotiate effectively.

5. Prepare for classification disputes — Expect increased scrutiny on whether imported chemicals are APIs or intermediates, whether products qualify as generics, and whether patent status is current. Document everything.

What Happens After June 12

The June 12 deadline is for initial applications — not final agreements. Commerce will review submissions, negotiate terms, and issue approvals on a rolling basis. The process is explicitly company-specific, meaning each agreement will have different terms based on the company's current manufacturing footprint, import volume, and onshoring commitments.

Companies that apply by June 12 and receive approval before their effective date (July 31 for Annex III, September 29 for others) enter the reduced tier from day one. Companies that apply late — or whose negotiations extend past their effective date — will pay the full 100% rate on entries made before their agreement is finalized, with no retroactive relief indicated in the current notice.

The 20% onshoring rate isn't permanent either. It expires April 2, 2030, at which point it rises to 100% if the company hasn't fulfilled its onshoring commitments. The clock starts ticking the moment your agreement is approved.

The Bigger Picture: A New Model for Tariff Relief

This isn't your standard exclusion process. Section 232 steel and aluminum let importers petition for product-level exclusions based on availability and harm. The pharmaceutical program is fundamentally different — it's a negotiated industrial policy instrument designed to force manufacturing relocation, not just adjust trade flows.

For the broader trade community, this represents a potential template. If company-specific onshoring agreements work for pharmaceuticals, expect similar frameworks for semiconductors, critical minerals, and other sectors where the administration has identified supply chain vulnerabilities.

The immediate question is execution. Can Commerce process what could be dozens or hundreds of applications within a window that's measured in weeks, not months? The July 31 deadline for Annex III companies means Commerce needs to have agreements in place within approximately 75 days of the June 12 submission date — an aggressive timeline for negotiations of this complexity.

The Bottom Line

The 100% pharmaceutical tariff is not a negotiating tactic that will be walked back. It's published, it has effective dates, and the compliance mechanism is now live. The only variable is what rate you'll actually pay — and that depends entirely on what you do in the next 30 days.

If you're importing patented pharmaceuticals or their ingredients, your June 12 deadline is real. The application goes to [email protected]. The difference between acting now and waiting is the difference between a 20% rate and a 100% rate — potentially hundreds of millions of dollars for large importers.

TariffLens is tracking the Section 232 pharmaceutical tariff codes across all affected HTS subheadings in Chapters 29 and 30. If you need to identify which of your entries fall under the new 9903.04.60-69 code family, our classification engine can flag exposed products automatically.

This article is for informational purposes only and does not constitute legal, tax, or customs advice. Consult a licensed customs broker or trade attorney for guidance specific to your situation.